Terms: = Breast cancer AND EML4, ENSG00000143924, 27436
25 results:
1. Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
Wiedemann C; Kazdal D; Cvetkovic J; Kunz J; Fisch D; Kirchner M; Kriegsmann M; Sültmann H; Heussel CP; Bischoff H; Thomas M; Stenzinger A; Christopoulos P
Cold Spring Harb Mol Case Stud; 2022 Oct; 8(6):. PubMed ID: 36207130
[TBL] [Abstract] [Full Text] [Related]
2. Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level.
Nakamura IT; Ikegami M; Hasegawa N; Hayashi T; Ueno T; Kawazu M; Yagishita S; Goto Y; Shinno Y; Kojima Y; Takamochi K; Takahashi F; Takahashi K; Mano H; Kohsaka S
Cancer Sci; 2021 May; 112(5):2006-2019. PubMed ID: 33484069
[TBL] [Abstract] [Full Text] [Related]
3. Malignant Pleural Effusion and Its Current Management: A Review.
Skok K; Hladnik G; Grm A; Crnjac A
Medicina (Kaunas); 2019 Aug; 55(8):. PubMed ID: 31443309
[TBL] [Abstract] [Full Text] [Related]
4. Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the eml4-ALK fusion gene.
Kometani T; Sugio K; Osoegawa A; Seto T; Ichinose Y
Thorac Cancer; 2018 May; 9(5):563-570. PubMed ID: 29517858
[TBL] [Abstract] [Full Text] [Related]
5. Recurrent eml4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.
Church AJ; Calicchio ML; Nardi V; Skalova A; Pinto A; Dillon DA; Gomez-Fernandez CR; Manoj N; Haimes JD; Stahl JA; Dela Cruz FS; Tannenbaum-Dvir S; Glade-Bender JL; Kung AL; DuBois SG; Kozakewich HP; Janeway KA; Perez-Atayde AR; Harris MH
Mod Pathol; 2018 Mar; 31(3):463-473. PubMed ID: 29099503
[TBL] [Abstract] [Full Text] [Related]
6. [Molecular-biological properties of edematous-infiltrative form of breast cancer].
Vopr Onkol; 2016; 62(4):485-9. PubMed ID: 30475534
[TBL] [Abstract] [Full Text] [Related]
7. Mutations of the EGFR, K-ras, eml4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
[TBL] [Abstract] [Full Text] [Related]
8. [Methodology of Establishing and Identifying NCI-H2228/Crizotinib-resistant Cell Lines In Vitro].
Wu D; Jin G; Zhao D; Zhang Y; Zhao J; Yu H
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):330-9. PubMed ID: 26104888
[TBL] [Abstract] [Full Text] [Related]
9. [Atypical metastatic breast localization in lung cancer].
Serraille A; Barazzutti H; Greillier L; Barlesi F
Rev Mal Respir; 2015 Nov; 32(9):953-5. PubMed ID: 26037683
[TBL] [Abstract] [Full Text] [Related]
10. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract] [Full Text] [Related]
11. Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells.
Khoo BL; Warkiani ME; Tan DS; Bhagat AA; Irwin D; Lau DP; Lim AS; Lim KH; Krisna SS; Lim WT; Yap YS; Lee SC; Soo RA; Han J; Lim CT
PLoS One; 2014; 9(7):e99409. PubMed ID: 24999991
[TBL] [Abstract] [Full Text] [Related]
12. Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations.
Secq V; Villeret J; Fina F; Carmassi M; Carcopino X; Garcia S; Metellus I; Boubli L; Iovanna J; Charpin C
Br J Cancer; 2014 Feb; 110(4):1045-52. PubMed ID: 24423920
[TBL] [Abstract] [Full Text] [Related]
13. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.
Chung C; Christianson M
J Oncol Pharm Pract; 2014 Feb; 20(1):11-28. PubMed ID: 23493335
[TBL] [Abstract] [Full Text] [Related]
14. Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer.
Schoppmann SF; Streubel B; Birner P
Eur J Cancer; 2013 May; 49(8):1876-81. PubMed ID: 23490651
[TBL] [Abstract] [Full Text] [Related]
15. Morphologic features of carcinomas with recurrent gene fusions.
Qi M; Li Y; Liu J; Yang X; Wang L; Zhou Z; Han B
Adv Anat Pathol; 2012 Nov; 19(6):417-24. PubMed ID: 23060067
[TBL] [Abstract] [Full Text] [Related]
16. Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Ong FS; Das K; Wang J; Vakil H; Kuo JZ; Blackwell WL; Lim SW; Goodarzi MO; Bernstein KE; Rotter JI; Grody WW
Expert Rev Mol Diagn; 2012 Jul; 12(6):593-602. PubMed ID: 22845480
[TBL] [Abstract] [Full Text] [Related]
17. Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.
Alarcon SV; Mollapour M; Lee MJ; Tsutsumi S; Lee S; Kim YS; Prince T; Apolo AB; Giaccone G; Xu W; Neckers LM; Trepel JB
Curr Mol Med; 2012 Nov; 12(9):1125-41. PubMed ID: 22804236
[TBL] [Abstract] [Full Text] [Related]
18. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
[TBL] [Abstract] [Full Text] [Related]
19. [Will targeted therapies replace chemotherapy?].
Collignon J; Jerusalem G
Rev Med Liege; 2012; 67 Spec No():29-36. PubMed ID: 22690483
[TBL] [Abstract] [Full Text] [Related]
20. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract] [Full Text] [Related]
[Next]
